In the ever-evolving landscape of medical research, the pursuit of effective cancer treatments continues to be a beacon of hope for millions. The recent announcement from Lisata Therapeutics Inc. (NASDAQ: LSTA) and WARPNINE about the completion of the iLSTA trial enrollment marks a pivotal moment in this pursuit. With compelling preliminary data consistent with earlier preclinical findings, there is growing evidence that certepetide, Lisata’s groundbreaking peptide agent, may significantly enhance the effectiveness of immunotherapy a promising development that warrants attention.Certepetide: A New Frontier in Cancer Treatment Certepetide has shown potential in preclinical studies for its ability to augmen...
Lisata Therapeutics: Pioneering Innovative Cancer Therapies with Promising Developments in Cholangiocarcinoma and Pancreatic Cancer Treatments In the ever-evolving landscape of oncology, Lisata Therapeutics, Inc. (Nasdaq: LSTA), a rising player in the field of clinical-stage pharmaceuticals, has made significant strides in the realm of advanced solid tumor treatments. Recently, the U.S. Food and Drug Administration (FDA) bestowed Orphan Drug Designation upon certepetide for the treatment of cholangiocarcinoma, a rare and aggressive form of bile duct cancer. This designation is pivotal, as it aims to encourage the development of therapies for conditions that affect fewer than 200,000 patients in the United St...
Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, is making significant progress in its clinical trials targeting advanced solid tumors and other serious diseases. The company recently announced major developments in its trials for Certepetide and LSTA1, which underscore its commitment to innovative therapeutic solutions. Phase 2a BOLSTER Trial of CertepetideOn April 3, 2024, Lisata Therapeutics announced the completion of patient enrollment for its Phase 2a BOLSTER trial of Certepetide as a first-line treatment for cholangiocarcinoma. Remarkably, this milestone was achieved nearly six months ahead of schedule. The BOLSTER trial aims to evaluate the safety and efficacy of Cer...
Lisata Therapeutics, a clinical-stage pharmaceutical company focused on developing groundbreaking therapies for advanced solid tumors and other critical diseases, is gearing up to make its presence felt in the industry with its participation in several highly anticipated events in April 2024. Led by the esteemed David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, the company aims to showcase its remarkable progress and commitment to revolutionizing cancer treatment.A Visionary Leader at the HelmDavid J. Mazzo, PhD, a revered figure in the pharmaceutical industry, has played a pivotal role in catapulting Lisata Therapeutics to the forefront of innovation. As the President and CEO of the comp...
In the domain of glioblastoma multiforme (GBM) research, Lisata Therapeutics triumphantly announced on January 17, 2024, the beginning of the next significant chapter in its cutting-edge story administering treatment of LSTA1 to the first patient in a promising Phase 2a trial. Basking Ridge, N.J.-based Lisata is focused on developing innovative therapies for a spectrum of formidable illnesses spanning advanced solid tumors and other grave conditions. Through its exploratory work in this area, it s contributing significant advancements in novel therapeutic schemes to tackle one of the most aggressive forms of brain cancer glioblastoma multiforme.Understanding the challenge presented by GBM, Lisata decided to ...
Sources:
Lisata Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Lisata Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Lisata Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
